Alexion Pharma (ALXN) Tops Q4 EPS by 40c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Reports Fourth Quarter and Full Year 2020 Results
February 4, 2021 8:00 AM EST4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96 Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021 Received EU approval for ULTOMIRIS® (ravulizumab) 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & atypical hemolytic uremic syndrome (aHUS) Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020
BOSTON--(BUSINESS... More
